Athira Puts Positive Spin on Alzheimer’s Trial Despite Missed Endpoint

Athira Pharma announced topline data from its exploratory ACT-AD Phase II trial of fosgonimeton in mild-to-moderate Alzheimer’s disease. The company is putting a positive spin on it, emphasizing positive subgroup analysis, but the trial missed the primary endpoint.